For decades, fertility evaluation has focused heavily on the female partner, while male fertility assessment often stops at a standard semen analysis. Yet clinically, many of us have seen couples where semen parameters look “normal,” but pregnancy simply does not happen. Emerging research suggests we may need to look more deeply, right down to sperm epigenetics.
A recent real-world clinical study published in the Journal of Assisted Reproduction and Genetics explored whether a newer sperm epigenetic test could better predict fertility treatment outcomes than traditional semen analysis alone.¹
This study followed more than 500 men whose U.S. clinicians ordered the epigenetic sperm test SpermQT over an 18-month period. Researchers compared pregnancy outcomes from intrauterine insemination (IUI) and IVF-ICSI cycles while adjusting for factors such as female partner age, sperm count, and treatment variables.¹
The goal was straightforward: determine whether sperm epigenetic health provides clinically useful predictive information beyond standard semen testing.
Epigenetics refers to chemical modifications affecting gene expression without altering the DNA sequence. In sperm, these modifications influence embryo development, implantation, and potentially even long-term offspring health.
A man can have normal sperm count, motility, and morphology, but still have epigenetic abnormalities affecting fertility potential. That discrepancy likely explains some cases of “unexplained infertility.”
The findings were striking:
- Abnormal epigenetic sperm results were associated with very poor IUI success rates.
- Some men with normal semen analyses still had underlying sperm issues detected by epigenetic testing.
- IVF-ICSI appeared capable of overcoming these epigenetic sperm factors in many cases.¹
Clinically, this suggests that some couples undergoing repeated unsuccessful IUIs might benefit from earlier escalation to IVF — potentially saving emotional energy, time, and financial resources.
From a clinician’s perspective, this research reinforces several important points:
Traditional semen parameters tell only part of the story.
If hidden sperm factors are identified early, couples may avoid ineffective treatments.
Fertility is always a couple’s issue, not just a female one.
As with any real-world observational study:
- Testing was ordered at physician discretion, introducing possible selection bias.
- Long-term reproductive outcomes need further confirmation.
- Cost-effectiveness and accessibility remain open questions.
This is promising research, but not yet a universal standard of care.
Regardless of advances in testing, one critical truth remains: sperm health is profoundly influenced by lifestyle factors—nutrition, environmental exposures, metabolic health, sleep, stress, and toxin burden.
In my clinical experience, optimizing these factors often improves semen quality and may also positively influence epigenetic profiles.
Technology can guide treatment decisions, but prevention and optimization remain foundational.
This type of research signals a shift toward precision fertility medicine — integrating molecular diagnostics, lifestyle optimization, and individualized treatment strategies.
That’s encouraging. It means fewer blind spots, fewer wasted treatment cycles, and hopefully better outcomes for couples navigating fertility challenges.
And importantly, it reminds us that male reproductive health deserves just as much attention as female fertility.
- Brogaard, Kristin, Susan Hudson, and Matthew VerMilyea. “Epigenetic Sperm Quality Testing for Predicting Fertility Treatment Success: A Real-World and Multi-Site Analysis.” Journal of Assisted Reproduction and Genetics, published online January 26, 2026. https://doi.org/10.1007/s10815-025-03791-0.
Dr Marina OBGYN